![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Places Arbutus’ Chronic Hepatitis B Virus IND Candidate Under Clinical Hold
FDA Places Arbutus’ Chronic Hepatitis B Virus IND Candidate Under Clinical Hold
Arbutus Biopharma’s AB-101 IND application to treat chronic hepatitis B virus (HBV) has been placed under an FDA clinical hold.
AB-101 is an oral PD-L1 inhibitor candidate intended to boost the immune system of patients by activating and reinvigorating specific T-cells and could, in combination with other drugs, “potentially lead to a functional cure in HBV,” the company said.
The agency communicated the news to the company verbally and will provide a letter to Arbutus within 30 days.
The investigational drug phase 1 single-ascending dose portion initial data will no longer be reported in the second half of 2023, the company said.
Related Topics
Upcoming Events
-
21Oct